Tag Archives: Catabasis

November, 2018

14 November
Catabasis and the University of Texas Southwestern Partner to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical Director of the Neuromuscular Cardiomyopathy Clinic at the University of Texas Southwestern (UT Southwestern) Medical Center as well as Co-Director of the National Institute of Health Sponsored UT …
Share

21 September
Catabasis to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23rd International Congress of the World Muscle Society, being held October 2 – 6, 2018, at the Intercontinental Hotel in Mendoza, Argentina. Presentations include: Late …
Share

27 June
Catabasis Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in DMD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add …
Share

4 October
Catabasis’ Edasalonexent Demonstrates Positive Mid-Stage Results in Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy results showing sustained disease-modifying effects in the MoveDMD trial open-label extension following 24 and 36 weeks of treatment with edasalonexent. Across all key assessments of muscle function, improvements were observed in the rate of decline after …
Share

8 June
New Data Supports Potential of Catabasis’ CAT-5571 as Novel Oral Treatment for Cystic Fibrosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announces positive preclinical data on CAT-5571, supporting its potential as an oral treatment for cystic fibrosis (CF). These data are being presented today at the 40th Annual European Cystic Fibrosis Society (ECFS) Conference in Seville, Spain. Patients with CF suffer …
Share

1 February
Catabasis’ Investigational Duchenne Muscular Dystrophy Drug Fails Mid-Stage Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2017– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line safety and efficacy results for Part B of the MoveDMD® trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD). The objective of Part B of the MoveDMD trial was to evaluate …
Share

25 January
Catabasis Announces Positive Top-Line Results from its Duchenne Muscular Dystrophy Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced positive top-line results from Part A of the MoveDMD trial, a Phase 1 / 2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD or Duchenne). All …
Share